Medtronic insertable cardiac monitor detects significantly higher rates of atrial fibrillation in large and small vessel stroke patients compared to standard of care

Dublin, june 7, 2021 /prnewswire/ -- medtronic plc (nyse:mdt), the global leader in medical technology, today announced clinical trial results from the stroke af trial demonstrating the superiority of the reveal linq™ insertable cardiac monitor (icm) to detect abnormal heartbeats, otherwise known as atrial fibrillation (af), in both large and small vessel stroke patients compared to standard of care. the findings were published in the june 1, 2021 issue of the journal of the american medical association (jama).
MDT Ratings Summary
MDT Quant Ranking